CCR5 and infection: Beginning 72 hours after infection with SHIV, eight animals received ARV therapy; leronlimab, a monoclonal IgG4 antibody that targets CCR5; and two bNAbs (PGT121‐M428L/N434S (LS) and VRC07‐523‐LS).